AvenCell Europe

AvenCell is a clinical-stage biotechnology company pioneering the development of switchable and controllable CAR-T cell therapies for oncology. The company's core technology, the UniCAR and RevCAR platforms, separates the antigen-targeting component from the T-cell, allowing for precise on/off control of therapeutic activity to enhance safety and efficacy. AvenCell was launched in 2021 as a joint venture between Blackstone Life Sciences, Intellia Therapeutics, and Cellex Cell Therapeutics, combining advanced cell manufacturing with CRISPR gene-editing capabilities. Its lead clinical programs, AVC-101 and AVC-201, target CD123 for the treatment of acute myeloid leukemia. With operations in Cambridge, Massachusetts, and Dresden, Germany, AvenCell is positioned to advance both autologous and allogeneic cell therapy candidates for hematological and solid tumor indications.